{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T08:07:40Z","timestamp":1750838860496,"version":"3.37.3"},"reference-count":19,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p>Although not formally highlighted as a risk factor in current practice guidelines, several observational studies have reported a possible association between antipsychotic use and development of venous thromboembolism (VTE). However, it is unclear to what extent the risk is elevated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case Report:<\/jats:title>\n                  <jats:p>Described are 2 cases of VTE following recent initiation of second-generation antipsychotics in elderly patients. Ms A was a 65-year-old woman with newly diagnosed bipolar I disorder who was hospitalized for acute mania and psychosis. She was treated with risperidone along with traditional mood stabilizers and developed a pulmonary embolism shortly after treatment initiation. Ms B was a 77-year-old woman with newly diagnosed bipolar I disorder who was hospitalized for depression and psychosis. She was treated with quetiapine and electroconvulsive therapy and developed a pulmonary embolism and deep vein thrombosis within 2 months of starting treatment. Risk assessment tools were not able to definitively predict the VTEs that developed in our patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>The association between antipsychotic medication and VTE has shown the highest risk with atypical antipsychotics, high dosages, and initiation within the past 3 months. Risk assessment tools may assist in assessing the risk of VTE in patients on antipsychotic therapy, although patients who are deemed by these tools to have minimal risk can still develop a VTE. Discussing VTE risk with patients when considering antipsychotic usage may help clinicians and patients safely determine the most appropriate treatment for their psychiatric illnesses while mitigating potential adverse effects.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2017.03.051","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T18:21:41Z","timestamp":1488392501000},"page":"51-55","source":"Crossref","is-referenced-by-count":3,"title":["Venous thromboembolism following initiation of atypical antipsychotics in two geriatric patients"],"prefix":"10.9740","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1332-3023","authenticated-orcid":false,"given":"Thomas J.","family":"Maestri","sequence":"first","affiliation":[{"name":"(Corresponding author) Clinical Assistant Professor, Xavier University of Louisiana College of Pharmacy, New Orleans, Louisiana, thom.maestri@gmail.com"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9562-0047","authenticated-orcid":false,"given":"Jessica","family":"Koenig","sequence":"first","affiliation":[{"name":"Psychiatry PGY-4, The University of Texas at Austin Dell Medical School, Austin, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4083-9623","authenticated-orcid":false,"given":"Christine","family":"Masuda","sequence":"first","affiliation":[{"name":"Psychiatry PGY-3, The University of Texas at Austin Dell Medical School, Austin, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7512-4919","authenticated-orcid":false,"given":"Tawny L.","family":"Smith","sequence":"first","affiliation":[{"name":"Assistant Professor, Psychiatry Residency Program, The University of Texas at Austin Dell Medical School at Seton Family of Hospitals, Austin, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6835-1910","authenticated-orcid":false,"given":"Erica C.","family":"Garcia-Pittman","sequence":"first","affiliation":[{"name":"Assistant Professor, Psychiatry Residency Program, The University of Texas at Austin Dell Medical School at Seton Family of Hospitals, Austin, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","reference":[{"issue":"2","key":"2020060307322261200_i2168-9709-7-2-51-b01","doi-asserted-by":"publisher","first-page":"7S","DOI":"10.1378\/chest.1412S3","article-title":"American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"issue":"8","key":"2020060307322261200_i2168-9709-7-2-51-b02","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/11633920-000000000-00000","article-title":"Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management","volume":"26","author":"J\u00f6nsson","year":"2012","journal-title":"CNS Drugs"},{"issue":"5","key":"2020060307322261200_i2168-9709-7-2-51-b03","first-page":"224","article-title":"Thrombosis hazard in chlorpromazine and reserpine therapy of endogenous psychoses [In German]","volume":"30","author":"Grahmann","year":"1959","journal-title":"Nervenarzt"},{"issue":"6","key":"2020060307322261200_i2168-9709-7-2-51-b04","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/00001648-199711000-00014","article-title":"Mortality in current and former users of clozapine","volume":"8","author":"Walker","year":"1997","journal-title":"Epidemiology"},{"issue":"5","key":"2020060307322261200_i2168-9709-7-2-51-b05","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2165\/00023210-199504050-00006","article-title":"Clozapine","volume":"4","author":"Wagstaff","year":"1995","journal-title":"CNS Drugs"},{"key":"2020060307322261200_i2168-9709-7-2-51-b06","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4245","article-title":"Antipsychotic drugs and risk of venous thromboembolism: nested case-control study","author":"Parker","year":"2010","journal-title":"BMJ"},{"issue":"22","key":"2020060307322261200_i2168-9709-7-2-51-b07","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1001\/archinte.165.22.2677","article-title":"Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents","volume":"165","author":"Liperoti","year":"2005","journal-title":"Arch Intern Med"},{"issue":"2","key":"2020060307322261200_i2168-9709-7-2-51-b08","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40264-013-0127-6","article-title":"Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies","volume":"37","author":"Barbui","year":"2014","journal-title":"Drug Saf"},{"issue":"1","key":"2020060307322261200_i2168-9709-7-2-51-b09","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1055\/s-0032-1316347","article-title":"Antipsychotics: a real or confounding risk factor for venous thromboembolism?","volume":"46","author":"Chapelle","year":"2012","journal-title":"Pharmacopsychiatry"},{"issue":"9237","key":"2020060307322261200_i2168-9709-7-2-51-b10","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0140-6736(00)02784-7","article-title":"Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study","volume":"356","author":"Zornberg","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"2020060307322261200_i2168-9709-7-2-51-b11","first-page":"205","article-title":"Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism","volume":"88","author":"Ray","year":"2002","journal-title":"Thromb Haemost"},{"issue":"5","key":"2020060307322261200_i2168-9709-7-2-51-b12","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1517\/14740330903117271","article-title":"Risk of venous thromboembolism due to antipsychotic drug therapy","volume":"8","author":"H\u00e4gg","year":"2009","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"2020060307322261200_i2168-9709-7-2-51-b13","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/pds.3699","article-title":"Antipsychotic drugs and risk of idiopathic venous thromboembolism: a nested case-control study using the CPRD","volume":"23","author":"Ishiguro","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2020060307322261200_i2168-9709-7-2-51-b14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/clpt.1981.15","article-title":"Plethysmographic comparison of sublingual and intramuscular ergotamine","volume":"29","author":"Winsor","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2020060307322261200_i2168-9709-7-2-51-b15","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"issue":"1","key":"2020060307322261200_i2168-9709-7-2-51-b16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1440-1819.2007.01773.x","article-title":"Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients","volume":"62","author":"Mal\u00fd","year":"2008","journal-title":"Psychiatry Clin Neurosci"},{"key":"2020060307322261200_i2168-9709-7-2-51-b17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4656","article-title":"Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study","author":"Hippisley-Cox","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"2020060307322261200_i2168-9709-7-2-51-b18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/01.yct.0000152572.27344.f5","article-title":"Pulmonary embolism after ECT","volume":"21","author":"Mamah","year":"2005","journal-title":"J ECT"},{"issue":"Suppl 4","key":"2020060307322261200_i2168-9709-7-2-51-b19","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/S0049-3848(09)70136-7","article-title":"Effects of race and ethnicity on the incidence of venous thromboembolism","volume":"123","author":"White","year":"2009","journal-title":"Thromb Res"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/7\/2\/51\/2095636\/mhc_2017_03_051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/7\/2\/51\/2095636\/mhc_2017_03_051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:22:16Z","timestamp":1731687736000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/7\/2\/article-p51.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,1]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2017.03.051","relation":{},"ISSN":["2168-9709"],"issn-type":[{"type":"electronic","value":"2168-9709"}],"subject":[],"published":{"date-parts":[[2017,3,1]]}}}